



THE STATE
of **ALASKA**
GOVERNOR MIKE DUNLEAVY

Department of Commerce, Community, & Economic Development

Corporations, Business, & Professional Licensing
Board of Pharmacy

P.O. Box 110806
Juneau, Alaska 99811-0806
Main: 907.465.2550
Fax: 907.465.2974

July 23, 2025

Statement Regarding Epinephrine Administration

On August 9, 2024, the U.S. Food and Drug Administration approved *neffy* (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who weigh at least 30 kilograms (about 66 pounds).^{1, 2}

Alaska Statute (AS) 08.80.030(b)(12), AS 08.80.168(e), and AS 17.22.010 codified the availability of epinephrine for the treatment of emergencies, identifying auto-injector as a method of administering epinephrine. This advisory seeks to make clear that the language in AS 08.80.030(b)(12), AS 08.80.168(e), and AS 17.22.010105 regarding the administration of epinephrine, **applies to ALL available, FDA-approved, pre-dosed forms of epinephrine.**

Sincerely,

A handwritten signature in cursive script that reads "Ashley Schaber".

Ashley Schaber, PharmD, MBA, BCPS
Chair, Alaska Board of Pharmacy

¹Press Release, U.S. Food & Drug Admin., FDA Approves First Nasal Spray for Treatment of Anaphylaxis (Aug. 9, 2024), *available at* <https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis>

² More information about *neffy*, including indications, dosing, and instructions for administration can be found on the product website: <https://neffypromo.com/>